Our Why

Cradle will revolutionize prenatal care and testing by
unlocking the cell to provide a complete picture of the
fetal genome. Mothers, families and physicians will now be
able to receive definitive information delivered at the
earliest stages of pregnancy.

Core Advantages

Currently, blood-based NIPT offers the highest level of performance for aneuploidy screening but it is inherently limited by relying on measuring circulating low-abundant DNA fragments. In contrast, Cradle’s patented technology isolates and utilizes intact cells at high purity leading to the following core advantages:

  • Earliest prenatal testing available
  • Highest accuracy in a non-invasive test
  • No patient limitations
  • Comprehensive genome analysis
  • Future testing for pregnancy complications

Sample Collection & Preservation

Cells are quickly and safely collected at the clinic, using a
routine, FDA approved and non-invasive procedure. The
sample is then stabilized and shipped to Cradle for analysis.

Our Lab Process

Cell Isolation

Fetal EVT cells are captured and purified using
a proprietary magnetic separation process

Fetal DNA Purification

High purity DNA is extracted from collected fetal EVT cells

Comprehensive Genome Analysis

Fetal DNA is analyzed on a genome sequencer

Interpretation and Clinical Reporting

Clinical results are provided in an intuitive, user-friendly report

Publications

Trophoblast Retrieval and Isolation from the Cervix (TRIC) for Noninvasive Prenatal Screening at 5 to 20 Weeks of Gestation

Fertility and Sterility 2014

Trophoblast Retrieval and Isolation from the Cervix (TRIC) is Unaffected by Early Gestational Age or Maternal Obesity

Prenatal Diagnosis 2015

Fetal Genome Profiling at 5 Weeks of Gestation After Noninvasive Isolation of Trophoblast Cells from the Endocervical Canal

Science Translational Medicine 2016

Altered Biomarkers in Trophoblast Cells Obtained Noninvasively Prior to Clinical Manifestation of Perinatal Disease

Scientific Reports 2016

Trophoblast Retrieval and Isolation from the Cervix: Origins of Cervical Trophoblasts and Their Potential Value for Risk Assessment of Ongoing Pregnancies

Human Reproduction Update 2018